BB&T Corp Boosts Holdings in Amgen, Inc. (AMGN)

BB&T Corp grew its holdings in shares of Amgen, Inc. (NASDAQ:AMGN) by 5.6% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 92,111 shares of the medical research company’s stock after acquiring an additional 4,863 shares during the quarter. BB&T Corp’s holdings in Amgen were worth $17,175,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of AMGN. CAPROCK Group Inc. increased its stake in shares of Amgen by 7.3% in the third quarter. CAPROCK Group Inc. now owns 8,043 shares of the medical research company’s stock worth $1,500,000 after buying an additional 547 shares during the period. Whittier Trust Co. increased its stake in shares of Amgen by 4.1% in the third quarter. Whittier Trust Co. now owns 34,219 shares of the medical research company’s stock worth $6,380,000 after buying an additional 1,334 shares during the period. Alpha Cubed Investments LLC increased its stake in shares of Amgen by 5.2% in the third quarter. Alpha Cubed Investments LLC now owns 88,352 shares of the medical research company’s stock worth $16,473,000 after buying an additional 4,370 shares during the period. APG Asset Management N.V. increased its stake in shares of Amgen by 1.3% in the third quarter. APG Asset Management N.V. now owns 1,614,772 shares of the medical research company’s stock worth $301,074,000 after buying an additional 20,300 shares during the period. Finally, Carnick & Kubik Group LLC increased its stake in shares of Amgen by 66.4% in the third quarter. Carnick & Kubik Group LLC now owns 18,166 shares of the medical research company’s stock worth $3,387,000 after buying an additional 7,246 shares during the period. 78.46% of the stock is currently owned by hedge funds and other institutional investors.

In other news, EVP Sean E. Harper sold 1,525 shares of the business’s stock in a transaction on Monday, October 9th. The shares were sold at an average price of $185.95, for a total transaction of $283,573.75. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Carbonnel Francois De sold 4,000 shares of the business’s stock in a transaction on Wednesday, November 8th. The shares were sold at an average price of $173.61, for a total transaction of $694,440.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 8,575 shares of company stock worth $1,509,339. Company insiders own 0.19% of the company’s stock.

Several brokerages recently commented on AMGN. Mizuho set a $192.00 target price on shares of Amgen and gave the stock a “buy” rating in a research note on Friday. Zacks Investment Research downgraded shares of Amgen from a “buy” rating to a “hold” rating in a research note on Monday, October 30th. Royal Bank of Canada decreased their target price on shares of Amgen from $192.00 to $188.00 and set a “sector perform” rating on the stock in a research note on Thursday, October 26th. Credit Suisse Group reaffirmed a “neutral” rating and issued a $186.00 target price (up from $177.00) on shares of Amgen in a research note on Friday, September 29th. Finally, Oppenheimer reaffirmed a “buy” rating and issued a $203.00 target price on shares of Amgen in a research note on Thursday, September 7th. One research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, ten have issued a buy rating and one has given a strong buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $189.94.

Amgen, Inc. (NASDAQ:AMGN) opened at $176.42 on Friday. The company has a current ratio of 6.07, a quick ratio of 5.72 and a debt-to-equity ratio of 1.05. The stock has a market cap of $128,250.00, a price-to-earnings ratio of 15.94, a price-to-earnings-growth ratio of 2.56 and a beta of 1.36. Amgen, Inc. has a 1 year low of $145.62 and a 1 year high of $191.10.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Wednesday, October 25th. The medical research company reported $3.27 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $3.11 by $0.16. The business had revenue of $5.77 billion for the quarter, compared to the consensus estimate of $5.75 billion. Amgen had a net margin of 35.54% and a return on equity of 29.90%. The company’s quarterly revenue was down .7% compared to the same quarter last year. During the same period in the previous year, the firm earned $3.02 EPS. equities research analysts predict that Amgen, Inc. will post 12.67 earnings per share for the current year.

Amgen announced that its Board of Directors has approved a share buyback plan on Wednesday, October 25th that allows the company to buyback $5.00 billion in outstanding shares. This buyback authorization allows the medical research company to reacquire shares of its stock through open market purchases. Stock buyback plans are often an indication that the company’s management believes its stock is undervalued.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 8th. Stockholders of record on Thursday, February 15th will be issued a dividend of $1.32 per share. This represents a $5.28 dividend on an annualized basis and a dividend yield of 2.99%. The ex-dividend date is Wednesday, February 14th. This is a boost from Amgen’s previous quarterly dividend of $1.15. Amgen’s payout ratio is 41.55%.

ILLEGAL ACTIVITY WARNING: “BB&T Corp Boosts Holdings in Amgen, Inc. (AMGN)” was originally reported by Community Financial News and is the property of of Community Financial News. If you are reading this piece on another domain, it was illegally stolen and republished in violation of US and international copyright legislation. The original version of this piece can be accessed at https://www.com-unik.info/2017/12/23/bbt-corp-boosts-holdings-in-amgen-inc-amgn.html.

Amgen Profile

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit